Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 8/20 | 0.70 |
| ▸ | BRAF | P15056 | 7/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.59 |
| ▸ | KDR | P35968 | 9/20 | 0.57 |
| ▸ | FLT1 | P17948 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12003876 | 0.99 | TNNI3K (0.69) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL1804035 | 0.91 | TNNI3K (0.80) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL1807210 | 0.90 | TNNI3K (0.88) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL6912165 | 0.89 | TNNI3K (0.83) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL6911696 | 0.89 | TNNI3K (0.81) | TNNI3KBRAFEGFR | |
| SCHEMBL6911101 | 0.89 | TNNI3K (0.59) | TNNI3KBRAFEGFRKDRFLT1 | |
| Trifluoroacetic Acid SCHEMBL12003553 | 0.86 | TNNI3K (0.80) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL6912489 | 0.83 | TNNI3K (0.80) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL6911135 | 0.83 | SRC (0.73) | TNNI3KBRAFEGFRKDRFLT1 | |
| SCHEMBL6910868 | 0.82 | TNNI3K (1.00) | TNNI3KBRAFEGFRKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | claimed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | claimed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | claimed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | TNNI3K 532/4885BRAF 1665/4885EGFR 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.